about
Low dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaThe effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionEffects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (APL))Idarubicin compared to other anthracyclines for treatment of newly diagnosed acute myeloid leukaemiaInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsClinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemiaAberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemiaDistinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosminMicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemiaA randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsTargeting CDK6 in cancer: State of the art and new insightsOxidative stress responses and NRF2 in human leukaemiaAllogeneic stem cell transplantation in first complete remissionNatural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) miceThe Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemiaPreferentially expressed antigen of melanoma (PRAME) in the development of diagnostic and therapeutic methods for hematological malignanciesQuantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemiaTherapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemiaCompounds from the marine sponge Cribrochalina vasculum offer a way to target IGF-1R mediated signaling in tumor cellsAKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicinDeregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistanceEvaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerA Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML PrognosisDistinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemiaA Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemiaFuture prospects of therapeutic clinical trials in acute myeloid leukemia.Gentle Massage Improves Disease- and Treatment-Related Symptoms in Patients with Acute Myelogenous Leukemia.Quantifying adhesion mechanisms and dynamics of human hematopoietic stem and progenitor cellsMolecular Dynamics Studies on D835N Mutation in FLT3-Its Impact on FLT3 Protein Structure.Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia.Proteomic analysis of transcription factor interactions in myeloid stem cell development and leukaemia.EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.Expression and prognostic significance of survivin in de novo acute myeloid leukaemia.
P2860
Q24186270-2C37644F-867C-430E-A9C7-A54B7DC917BCQ24186284-BEF31ADC-572A-4960-A1B7-F07C8209B6A0Q24187297-3121D9D6-2D60-4BFC-B0BA-2F7B3130A805Q24187927-AD4E91B8-7818-4FB4-8464-34B6D3CDD63EQ24188096-69F3B326-8443-4B17-800A-DA5BE7BC7733Q24200407-BF82A8BF-139E-40AC-AA8D-E5D28C04BE90Q24202630-7BE55385-B957-4327-AF3E-5E1494C432D9Q24234645-6C452EFB-FD0D-4C1B-B45B-4A6EC921CC76Q24234680-88D09EC6-F306-467F-8F1F-B53EFC98FFCFQ24617091-4A701723-C7C4-47A8-BFF2-F98C9CC88B01Q24621923-B802CB96-6C58-498F-B950-5A45689E1017Q24624389-2F9D3F31-F4AA-4900-99DE-14168D037942Q24652323-31EFC38E-EF43-4156-ABD8-B63EBA045CDEQ24655915-928C1DBD-8E92-4653-8309-B6A377D295BFQ24801336-6760C1C5-1D29-4980-83F3-CE8DE4BF8668Q26745731-21FE532E-EE79-4D99-91DC-C423BE413DF8Q26796499-BB3C36E0-F196-4F13-B873-ADDC25E3E40BQ26864239-04959830-16BF-44C0-AA69-E205FF54A1A4Q26996818-DBE52912-16A7-4342-A100-514173AD5C8DQ27318729-E7BE5402-6A6D-4D87-B76C-1F8A806CB732Q27335047-6521C1A9-BE93-47E7-9563-9C263E798D20Q28190215-01F6084D-4686-432E-8F92-EB435DDDCF72Q28212054-89EB3374-D401-47A9-893E-0F99F24E5661Q28354257-4BAB92AF-7BC7-4B0A-8675-85A7BC7F3050Q28468664-458AB4B2-5A94-4DBC-8C0A-222917F060EAQ28484890-03EB44A6-C82F-4B53-A4CF-46117CAC7594Q28538139-4EECD319-36C6-4E44-B78C-E728038B57D1Q28538435-D2AC7AF4-B72C-4838-B21A-A2128D8CC55CQ28597169-36ADA2BF-E5D8-40FE-81DD-7B05AD603080Q28749564-C0F45107-79D1-4A97-B46C-6B51985378E3Q28820781-1D8A115C-9A95-4A20-A4F0-962B8E330861Q30244168-9061D452-6EE7-4F12-9031-E8CAF9FDB8EDQ30301087-C954BF25-98D2-4140-8A2B-7B50B6B4421AQ30358968-FAF8EA2F-9E4E-4022-A816-13BD4B631EF5Q30381343-AB3099AA-D2FC-427F-8CB0-604954950F08Q30444746-71233A77-475D-4479-B416-F37F7B149625Q31030133-85E9C519-88ED-435A-96CC-F601A18F772BQ31108865-BCBC2798-5654-4026-BFC7-7B8CB21762CFQ33112273-95FCFA6B-384B-427E-BD84-9410D0041A98Q33181478-B83417C3-93D1-4202-9353-7888045134FE
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Acute myeloid leukemia.
@ast
Acute myeloid leukemia.
@en
type
label
Acute myeloid leukemia.
@ast
Acute myeloid leukemia.
@en
prefLabel
Acute myeloid leukemia.
@ast
Acute myeloid leukemia.
@en
P2093
P1476
Acute myeloid leukemia.
@en
P2093
Downing JR
Löwenberg B
P304
P356
10.1056/NEJM199909303411407
P407
P577
1999-09-01T00:00:00Z